Lenire Biosciences Completes License Agreement with University College London for VSN16R, A Novel Clinical Candidate Treatment for Fragile X Syndrome
SAN DIEGO, June 16, 2022 (GLOBE NEWSWIRE) — Lenire Biosciences Inc., a biopharmaceutical company developing…
Getting Value From AI Takes More Than Buying The Tools
Keeper Security and Tenable Integrate to Streamline Cloud Risk Detection, Remediation and Vulnerability Assessment
The Tech Interactive Announces Seismic Valley: The Earthquake Experience, Coming Summer 2027